CTIS2023-503522-40-00进行中（未招募）1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis - ANB032-201
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •Male or female aged 18 to 65 years and in good general health, Moderate or severe atopic dermatitis for at least 6 months prior to randomization, History of inadequate response to treatment for atopic dermatitis with topical medications or for whom topical treatments are otherwise medically inadvisable, EASI score >=16 at Screening and at Randomization, vIGA-AD score >=3 at Screening and at Randomization, AD-involved BSA>=10% at Screening and at Randomization
排除标准
- •Any factors that in the Investigator's opinion would predispose the subject to develop an infection, Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status, Not able to tolerate SC drug administration, Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization, Received or plans to initiate during the study any of the following prescribed medications or therapies: Systemic Janus kinase (JAK) inhibitors at any time prior to Day 1, Immunomodulatory biologic agents received within 12 weeks or 5 half lives (t1/2; whichever is longer) before Day 1, Phototherapy treatment or laser therapy that could affect disease severity or interfere with disease assessments within 4 weeks before Day 1, Systemic therapy for AD, including but not limited to, corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE 4) inhibitors, IFN ?, and mycophenolate mofetil within 4 weeks before Day 1, Use of topical treatments for AD including but not limited to corticosteroids, tacrolimus, pimecrolimus, JAK inhibitors, or PDE-4 inhibitors within 14 days before Day 1, Live or live attenuated vaccines within 12 weeks before Day 1
研究者
相似试验
进行中（未招募）
不适用
A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial CystitisBladder Pain Syndrome / Interstitial CystitisMedDRA version: 14.1Level: LLTClassification code 10071166Term: Bladder pain syndromeSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008928Term: Chronic interstitial cystitis NOSSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: LLTClassification code 10008927Term: Chronic interstitial cystitisSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 14.1Level: PTClassification code 10011796Term: Cystitis interstitialSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2011-004555-39-NLAstellas Pharma Europe B.V.300
进行中（未招募）
1 期
A study to investigate how safe and able to produce an effect in the body study drug VX-150 is in patients with pain that typically begins in the feet or handPain Caused by Small Fiber NeuropathyMedDRA version: 20.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.1Level: PTClassification code 10073928Term: Small fibre neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2017-001042-10-ITVERTEX PHARMACEUTICALS INCORPORATED89
招募中
1 期
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With SchizophreniaPatients with schizophrenia who are experiencing an acute exacerbation of psychosisMedDRA version: 20.0Level: HLGTClassification code 10039628Term: Schizophrenia and other psychotic disordersSystem Organ Class: 10037175 - Psychiatric disordersMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2022-000581-17-BGCerevel Therapeutics, LLC600
进行中（未招募）
1 期
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study of Cicletanine in Subjects with Pulmonary Arterial HypertensioEUCTR2008-007455-26-BEGilead Sciences, Inc.160
尚未招募
2 期
A study to calculate efficacy and safety of SAR441566 in adults with rheumatoid arthritisCTRI/2024/05/067017Sanofi Healthcare India Pvt Limited (SHIPL)